PL4225351T1 - Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym - Google Patents

Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym

Info

Publication number
PL4225351T1
PL4225351T1 PL21880926.7T PL21880926T PL4225351T1 PL 4225351 T1 PL4225351 T1 PL 4225351T1 PL 21880926 T PL21880926 T PL 21880926T PL 4225351 T1 PL4225351 T1 PL 4225351T1
Authority
PL
Poland
Prior art keywords
active ingredient
therapueutic
vaccine
composition
combination
Prior art date
Application number
PL21880926.7T
Other languages
English (en)
Inventor
Tim Ioannides
Evangelos V. BADIAVAS
Original Assignee
Hpvvax, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/068,087 external-priority patent/US11813329B2/en
Application filed by Hpvvax, Llc filed Critical Hpvvax, Llc
Publication of PL4225351T1 publication Critical patent/PL4225351T1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21880926.7T 2020-10-12 2021-10-12 Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym PL4225351T1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/068,087 US11813329B2 (en) 2014-10-24 2020-10-12 Method and composition for treating cancer or skin lesion using a vaccine
PCT/US2021/054622 WO2022081604A1 (en) 2020-10-12 2021-10-12 Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient

Publications (1)

Publication Number Publication Date
PL4225351T1 true PL4225351T1 (pl) 2023-12-11

Family

ID=81208565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21880926.7T PL4225351T1 (pl) 2020-10-12 2021-10-12 Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym

Country Status (16)

Country Link
EP (1) EP4225351A4 (pl)
JP (1) JP2023546073A (pl)
KR (1) KR20230117106A (pl)
AU (1) AU2021360676B2 (pl)
CA (1) CA3195478A1 (pl)
CO (1) CO2023006083A2 (pl)
CY (1) CY20232200001T2 (pl)
DE (1) DE21880926T1 (pl)
DK (1) DK4225351T1 (pl)
ES (1) ES2962700T1 (pl)
FI (1) FI4225351T1 (pl)
HU (1) HUE21880926T1 (pl)
IL (1) IL302098A (pl)
MX (1) MX2023004285A (pl)
PL (1) PL4225351T1 (pl)
WO (1) WO2022081604A1 (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
CN105597092A (zh) * 2014-11-24 2016-05-25 北京凯因科技股份有限公司 含有白介素15的防治hpv感染的疫苗喷雾剂
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
JP7033788B2 (ja) * 2015-10-09 2022-03-11 グローバル バイオファーマ インコーポレイテッド 組み合わせ医薬
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax, Llc. métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica
ES2891578T3 (es) * 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
US20190161530A1 (en) * 2016-04-07 2019-05-30 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions

Also Published As

Publication number Publication date
DE21880926T1 (de) 2024-01-11
AU2021360676B2 (en) 2025-09-04
KR20230117106A (ko) 2023-08-07
CY20232200001T2 (el) 2024-02-16
WO2022081604A1 (en) 2022-04-21
ES2962700T1 (es) 2024-03-20
FI4225351T1 (fi) 2023-10-20
CO2023006083A2 (es) 2023-08-18
JP2023546073A (ja) 2023-11-01
AU2021360676A9 (en) 2024-10-10
DK4225351T1 (da) 2023-10-23
AU2021360676A1 (en) 2023-06-15
EP4225351A4 (en) 2024-10-09
EP4225351A1 (en) 2023-08-16
IL302098A (en) 2023-06-01
HUE21880926T1 (hu) 2024-04-28
CA3195478A1 (en) 2022-04-21
MX2023004285A (es) 2023-06-19

Similar Documents

Publication Publication Date Title
EP4097122A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
ZA202201019B (en) Synergistic stable nitrogen fertilizer and preparation method
EP4243797A4 (en) PLATFORM FOR RAPID INFUSION AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS
MX370624B (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
EP4196476A4 (en) METHOD AND COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF NETOSIS
EP4210714A4 (en) TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
IL277315B (en) Method and preparations for treating the corona virus infection
IL299950A (en) Superantigen conjugate for use in methods and compositions for the treatment of cancer
EP4445914A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE
IL325645A (en) Pharmaceutical composition for treating baldness, method of preparation and use thereof
GB202306292D0 (en) Methods and compositions for cellular therapy
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
PL4225351T1 (pl) Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym
HK40091555A (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
GB2626658B (en) Composition, method and use
EP4620468A4 (en) BUTADIENE-CYCLODEXTRIN INCLUSION COMPLEX, PHARMACEUTICAL COMPOSITION, PROCESS OF PREPARATION AND ASSOCIATED USE
EP3723766A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT, MITIGATION OR PREVENTION OF MUSCLE CRAMPS, CONTAINING CHOLINE ALFOSCERATE AS ACTIVE INGREDIENT
GB202016863D0 (en) Microrna-29 compounds, compositions and uses in therapy
GB202107977D0 (en) Method, composition and use
KR102627070B9 (ko) 미생물, 및 면역관문 억제제를 유효성분으로 포함하는, 고 당분 환경에서의 뇌종양 예방 또는 치료용 조성물
GB202201935D0 (en) Methods and compositions for treating cancer in taxane-resistant patients
HK40096032A (en) Method and compound for use, in treating and/or preventing netosis
AU2021903484A0 (en) Methods and compositions for treating skin
CA3295701A1 (en) Pharmaceutical formulation for treating alopecia, preparation method therefor and use thereof
HK40125906A (en) Compositions and methods for reducing adverse side effects in cancer treatment